Celltrion Inc., a major South Korean biopharmaceutical company, said Friday it has launched its biosimilar Avtozma for the ...

Subcutaneous Saphnelo may offer people with lupus more convenient dosing with efficacy similar to the approved infusion version of the therapy, data show.

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental ...

Highlights from CTAD 2025 include GLP-1 agonist data, p-tau217 biomarker utility, subcutaneous lecanemab trials, and racial disparities in trial enrollment.

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

The US regulator expects to issue a decision on Eisai's application for Leqembi Iqlik, which it has granted priority review, by May 24.

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease ...

The new generic drug has been approved for treatment of bovine respiratory disease and associated pyrexia in beef and ...

BD and Ypsomed will expand their collaboration through the development of a 5.5 ml version of BD’s Neopak XtraFlow glass ...